Oral melanoma in dogs.

What it is

Oral melanoma is a malignant tumor of the pigment-producing cells (melanocytes) in the mouth. It can show up on the gums, the inside of the lips, the tongue, or the palate. The tumor may be heavily pigmented (dark/black) or amelanotic (lacking pigment, often red or pink) — visual pigmentation alone does not confirm or rule out melanoma.

Unlike human cutaneous melanoma, canine oral melanoma is not driven by UV exposure. Its biology has more in common with human mucosal melanoma — a rarer human variant — which is why canine oral melanoma is one of the most-studied comparative oncology models.

Signs to watch for

• A new dark or pink mass in the mouth, often noticed during teeth brushing or by the vet at a routine exam.
• Bad breath, drooling, or blood-tinged saliva. Particularly if it's new or worsening.
• Difficulty eating or chewing, or dropping food from one side of the mouth.
• Loose teeth or facial swelling. Oral melanoma can invade underlying bone.

How veterinarians diagnose it

Definitive diagnosis requires biopsy — fine-needle aspiration can miss oral melanoma, so a true tissue sample (incisional or excisional biopsy) is the standard.

Staging is critical because oral melanoma metastasizes early: skull CT or detailed dental radiographs to assess local bone invasion, three-view chest radiographs (or thoracic CT) for lung mets, and aspiration of the mandibular and retropharyngeal lymph nodes — even normal-feeling ones.

What treatment usually looks like

• Aggressive local control — surgery (mandibulectomy or maxillectomy) when feasible. Dogs adapt to most resections well; cosmetic outcome improves with surgeon experience.
• Radiation as a primary therapy for inoperable tumors or as an adjunct when surgical margins are tight.
• Oncept melanoma vaccine (xenogeneic human tyrosinase DNA) — USDA-licensed for dogs with stage II/III oral melanoma after local control. Best-studied adjuvant in this disease.
• Checkpoint inhibitor immunotherapy is an active area of clinical-trial research; ask about availability.

Prognosis

Stage at diagnosis is the strongest predictor of outcome. Stage I (small primary, no spread) treated with aggressive local control plus the Oncept vaccine has the best outcomes — median survival measured in years for some dogs. Stage III/IV disease (lymph node or distant metastasis) carries a much shorter median survival, typically in the months range.

Histologic features (mitotic count, nuclear atypia, Ki-67 index) refine prognosis further. Your oncologist can integrate these into a specific outlook for your dog.

Questions to ask your vet

• What stage is the cancer? Has it spread to lymph nodes or lungs?
• Is the tumor location amenable to surgery? What will my dog look like and eat like after?
• Is the Oncept vaccine appropriate here? When in the treatment sequence?
• Are there checkpoint inhibitor or other immunotherapy trials we should consider?
• What's a realistic survival range for our specific stage?
• What does end-of-life care look like for oral cancers if we don't pursue aggressive therapy?

Where to learn more

Veterinary teaching hospitals at most accredited US vet schools maintain owner-facing fact sheets on common cancers. Peer-reviewed journals — JAVMA, Veterinary and Comparative Oncology, Frontiers in Veterinary Science — are accessible through PubMed. The American College of Veterinary Internal Medicine (ACVIM) and the Veterinary Cancer Society publish consensus statements you can ask your vet to walk you through.

For clinical trials enrolling dogs with this diagnosis, see the SciRouter Vet trial finder — we index AVMA, NCI COTC, and twelve university registries.